Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

被引:18
|
作者
Rommasi, Foad [1 ]
Nasiri, Mohammad Javad [2 ]
Mirsaeidi, Mehdi [3 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[3] Univ Miami, Miller Sch Med, Dept Pulm & Crit Care, Miami, FL 33136 USA
关键词
SARS-CoV-2; Pathophysiology; COVID-19; treatment; Inflammatory responses; Immunosuppressive agents; Cytokine storm; NECROSIS-FACTOR-ALPHA; CORONAVIRUS DISEASE 2019; RHEUMATOID-ARTHRITIS; CLINICAL PHARMACOKINETICS; RECEPTOR ANTAGONIST; IN-VITRO; ABSOLUTE BIOAVAILABILITY; COLCHICINE THERAPY; CYTOKINE STORM; MELATONIN;
D O I
10.1007/s11010-021-04325-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
引用
收藏
页码:711 / 726
页数:16
相关论文
共 50 条
  • [41] Tetracycline and viruses: a possible treatment for COVID-19?
    Mosquera-Sulbaran, Jesus A.
    Hernandez-Fonseca, Hugo
    ARCHIVES OF VIROLOGY, 2021, 166 (01) : 1 - 7
  • [42] Neurological manifestations in COVID-19 and its possible mechanism
    Tang, Xiaojia
    Luo, Yuhan
    Song, Yuxia
    Fan, Hongyang
    Dong, Sisi
    Liu, Peipei
    Chen, Yingzhu
    AGING-US, 2020, 12 (18): : 18754 - 18764
  • [43] COVID-19: immunopathology and its implications for therapy
    Xuetao Cao
    Nature Reviews Immunology, 2020, 20 : 269 - 270
  • [44] A mouse model of COVID-19 associated immunopathology
    Pimenov, Lisabeth
    Gawish, Riem
    Starkl, Philipp
    Hladik, Anastasiya
    Lakovits, Karin
    Repic, Anna Ohradanova
    Oostenbrink, Chris
    Agerer, Benedikt
    Bergthaler, Andreas
    Knapp, Sylvia
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 349 - 349
  • [45] Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
    Mamber, Stephen W.
    Krakowka, Steven
    Osborn, Jeffrey
    Saberski, Lloyd
    Rhodes, Ryan G.
    Dahlberg, Albert E.
    Pond-Tor, Sunthorn
    Fitzgerald, Kara
    Wright, Neal
    Beseme, Sarah
    McMichael, John
    MSPHERE, 2020, 5 (03):
  • [46] COVID-19: immunopathology and its implications for therapy
    Cao, Xuetao
    NATURE REVIEWS IMMUNOLOGY, 2020, 20 (05) : 269 - 270
  • [47] On the Alert for Cytokine Storm: Immunopathology in COVID-19
    Henderson, Lauren A.
    Canna, Scott W.
    Schulert, Grant S.
    Volpi, Stefano
    Lee, Pui Y.
    Kernan, Kate F.
    Caricchio, Roberto
    Mahmud, Shawn
    Hazen, Melissa M.
    Halyabar, Olha
    Hoyt, Kacie J.
    Han, Joseph
    Grom, Alexei A.
    Gattorno, Marco
    Ravelli, Angelo
    De Benedetti, Fabrizio
    Behrens, Edward M.
    Cron, Randy Q.
    Nigrovic, Peter A.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (07) : 1059 - 1063
  • [48] Investigational immunomodulatory therapies for COVID-19
    Assi, M.
    Koshy, K. M.
    El Atrouni, W.
    Burke, K.
    Berg, M.
    Opardija, A.
    Temesgen, Z.
    DRUGS OF THE FUTURE, 2021, 46 (09) : 711 - 729
  • [49] COVID-19 pandemic: mechanism, diagnosis, and treatment
    Kumar, Vinay
    Doshi, Khushi U.
    Khan, Wajihul H.
    Rathore, Anurag S.
    JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, 2021, 96 (02) : 299 - 308
  • [50] Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19
    Martonik, Diana
    Parfieniuk-Kowerda, Anna
    Starosz, Aleksandra
    Grubczak, Kamil
    Moniuszko, Marcin
    Flisiak, Robert
    FRONTIERS IN IMMUNOLOGY, 2023, 14